Article Sidebar
Views PDF: 65
SURVEY ON CONTENTS OF OSTEOPROTEGERIN PRESENTATION IN PATTERNS AFTER NON TREATMENT
Main Article Content
Abstract
Objectives: To investigate the change in plasma osteoprotegerin (OPG) concentration and its relationship with some patient characteristics 6 months after kidney transplantation. Subjects: Study subjects included 188 people, divided into 2 groups: 108 patients with end-stage chronic kidney disease before kidney transplant, 84 patients in the post-transplant follow-up group and 80 healthy people in the control group. All patients had plasma OPG levels quantified by ELISA method. Results: After 6 months of kidney transplant, the rate of increase in urea was 15.5% and increase in creatinine was 36.9%. There are 31% of patients with reduced glomerular filtration rate <60ml/p while post-transplant proteinuria only 2 patients (2.4%). After transplantation, the indicators of improvement were anemia, CRP inflammatory factor compared with pre-transplant were significant with p<0.05. Other factors still account for a high proportion after transplantation: Hypertension (66.7%), dyslipidemia (67.1%). There are 2 patients (2.4%) with diabetes after transplantation. The average OPG concentration in patients after 6 months of kidney transplant was 10.2 pmol/L, compared with 56.25 pmol/L before kidney transplant, the difference was significant with p<0.001. The proportion of patients with decreased OPG concentration was 39.3%, and high OPG concentration was 60.7%. The AIP atherosclerotic index in the group with reduced OPG concentration to normal was lower than that in the group with high OPG concentration after transplantation, with p<0.05. Conclusion: OPG concentration in patients 6 months after kidney transplant decreased compared to before kidney transplant, significant with p<0.001. The proportion of patients with decreased OPG concentration was 39.3%, and high OPG concentration was 60.7%. The AIP atherosclerotic index in the group with reduced OPG concentration to normal was lower than that in the group with high OPG concentration after transplantation, with p<0.05.
Article Details
Keywords
End stage chronic kidney disease, Osteoprotegerin, Atherosclerosis, Kidney transplant.
References
2. Akchurin O.M. (2019). Chronic kidney disease and dietary measures to improve outcomes. Pediatr Clin North Am, 66(1), 247–267.
3. Roumeliotis S., Mallamaci F., and Zoccali C. (2020). Endothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update. J Clin Med, 9(8), 2359.
4. Kobiyama K. and Ley K. (2018). Atherosclerosis: A Chronic Inflammatory Disease with an Autoimmune Component. Circ Res, 123(10), 1118–1120.
5. Gupta V., Ekundayo O., Nemeth Z.K., et al. (2021). Association between serum osteoprotegerin level and mortality in kidney transplant recipients - a prospective observational cohort study. Transpl Int, 34(5), 844–854.
6. Kolonko A., Chudek J., Szotowska M., et al. (2016). Cardiovascular Risk Factors and Markers of Atherosclerosis in Stable Kidney Transplant Recipients. Transplantation Proceedings, 48(5), 1543–1550.
7. Nguyễn Thị Thu Hà (2022), Nghiên cứu kháng thể kháng HLA và mối liên quan đến đặc điểm lâm sàng và cận lâm sàng ở bệnh nhân ghép thận, Học viện Quân Y.
8. Krzanowski M., Krzanowska K., Dumnicka P., et al. (2018). Elevated Circulating Osteoprotegerin Levels in the Plasma of Hemodialyzed Patients With Severe Artery Calcification. Ther Apher Dial, 22(5), 519–529.
9. Chen Y.-C., Hsu B.-G., Ho C.-C., et al. (2017). Elevated serum osteoprotegerin may predict peripheral arterial disease after kidney transplantation: a single-center prospective cross-sectional study in Taiwan. PeerJ, 5, e3847.
10. Reggiani F., Moroni G., and Ponticelli C. (2022). Cardiovascular Risk after Kidney Transplantation: Causes and Current Approaches to a Relevant Burden. J Pers Med, 12(8), 1200.